Advertisement

Viral Cardiac Infections

  • Brian F. BirnbaumEmail author
  • Charles E. Canter
Chapter
  • 354 Downloads

Abstract

Viral infections can affect the pediatric heart in a multitude of ways. The two most common viral cardiac processes are myocarditis and pericarditis. Numerous viruses have been implicated in these disease states. In addition to direct viral effects on the myocardium and pericardium, inflammatory mediators also play a role in these conditions. A high index of suspicion, thorough history and physical examination, along with directed laboratory testing, electrocardiography and echocardiography are necessary for the diagnosis and management of myocarditis and pericarditis. Occasionally, more advanced studies such as magnetic resonance imaging (MRI) and endomyocardial biopsy may be useful. Finally, human immunodeficiency virus (HIV) can have a number of cardiac related effects. Children with HIV, require routine cardiac monitoring and counseling.

Keywords

Human Immunodeficiency Virus Cardiac Magnetic Resonance Late Gadolinium Enhancement Pericardial Effusion Acute Decompensated Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93(5):841–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Imazio M. Contemporary management of pericardial diseases. Curr Opin Cardiol. 2012;27(3):308–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Kyto V, Saraste A, Voipio-Pulkki LM, Saukko P. Incidence of fatal myocarditis: a population-based study in Finland. Am J Epidemiol. 2007;165(5):570–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Weber MA, Ashworth MT, Risdon RA, Malone M, Burch M, Sebire NJ. Clinicopathological features of paediatric deaths due to myocarditis: an autopsy series. Arch Dis Child. 2008;93(7):594–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004;180(3):110–2.PubMedGoogle Scholar
  6. 6.
    Puranik R, Chow CK, Duflou JA, Kilborn MJ, McGuire MA. Sudden death in the young. Heart Rhythm. 2005;2(12):1277–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):622–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Kyto V, Sipila J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Fairweather D, Cooper Jr LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7–46.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Huber SA, Job LP, Auld KR. Influence of sex hormones on coxsackie B-3 virus infection in Balb/c mice. Cell Immunol. 1982;67(1):173–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. 2003;34(5):497–503.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearney D, Zhang YH, Bodurtha J, Gelb B, Ni J, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 1994;90(1):330–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Kashimura T, Kodama M, Hotta Y, Hosoya J, Yoshida K, Ozawa T, Watanabe R, Okura Y, Kato K, Hanawa H, Kuwano R, Aizawa Y. Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. Virchows Arch. 2004;444(3):283–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Camargo PR, Okay TS, Yamamoto L, Del Negro GM, Lopes AA. Myocarditis in children and detection of viruses in myocardial tissue: implications for immunosuppressive therapy. Int J Cardiol. 2011;148(2):204–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Baruteau AE, Boimond N, Ramful D. Myocarditis associated with 2009 influenza A (H1N1) virus in children. Cardiol Young. 2010;20(3):351–2.PubMedCrossRefGoogle Scholar
  17. 17.
    Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, Smoot E, Rice TW, Loftis LL, Helfaer M, Doctor A, Paden M, Flori H, Babbitt C, Graciano AL, Gedeit R, Sanders RC, Giuliano JS, Zimmerman J, Uyeki TM; Pediatric Acute Lung Injury and Sepsis Investigator’s Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450–8.Google Scholar
  18. 18.
    Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102(6–7):559–68.PubMedCrossRefGoogle Scholar
  19. 19.
    Premkumar M, Rangegowda D, Vashishtha C, Bhatia V, Khumuckham JS, Kumar B. Acute viral hepatitis e is associated with the development of myocarditis. Case Reports Hepatol. 2015;2015:458056.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Bohm M. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol. 2001;39(12):4585–7.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Simpson KE, Storch GA, Lee CK, Ward KE, Danon S, Simon CM, Delaney JW, Tong A, Canter CE. High frequency of detection by PCR of viral nucleic acid in the blood of infants presenting with clinical myocarditis. Pediatr Cardiol. 2016;37(2):399–404.PubMedCrossRefGoogle Scholar
  23. 23.
    Dec Jr GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985;312(14):885–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Ni J, Bowles NE, Kim YH, Demmler G, Kearney D, Bricker JT, Towbin JA. Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation. 1997;95(1):133–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Saphir O, Field M. Complications of myocarditis in children. J Pediatr. 1954;45(4):457–63.PubMedCrossRefGoogle Scholar
  26. 26.
    Woodruff JF. Viral myocarditis. A review. Am J Pathol. 1980;101(2):425–84.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008;3:127–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006;124(1):119–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Noutsias M, Fechner H, de Jonge H, Wang X, Dekkers D, Houtsmuller AB, Pauschinger M, Bergelson J, Warraich R, Yacoub M, Hetzer R, Lamers J, Schultheiss HP, Poller W. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation. 2001;104(3):275–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackievirus B3 replication. J Immunol. 1987;139(3):913–8.PubMedGoogle Scholar
  31. 31.
    Henke A, Huber S, Stelzner A, Whitton JL. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol. 1995;69(11):6720–8.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Hayder H, Mullbacher A. Molecular basis of immune evasion strategies by adenoviruses. Immunol Cell Biol. 1996;74(6):504–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Tavares PS, Rocon-Albuquerque Jr R, Leite-Moreira AF. Innate immune receptor activation in viral myocarditis: pathophysiologic implications. Rev Port Cardiol. 2010;29(1):57–78.PubMedGoogle Scholar
  34. 34.
    Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 1994;89(2):846–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S. Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation. 1994;89(6):2836–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Shioi T, Matsumori A, Nishio R, Ono K, Kakio T, Sasayama S. Protective role of interleukin-12 in viral myocarditis. J Mol Cell Cardiol. 1997;29(9):2327–34.PubMedCrossRefGoogle Scholar
  37. 37.
    Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol. 1993;22(4 Suppl A):99A–105A.PubMedCrossRefGoogle Scholar
  38. 38.
    Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177(11):8234–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L, Thiene G, Iliceto S. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008;41(1):35–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Mascaro-Blanco A, Alvarez K, Yu X, Lindenfeld J, Olansky L, Lyons T, Duvall D, Heuser JS, Gosmanova A, Rubenstein CJ, Cooper LT, Kem DC, Cunningham MW. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity. 2008;41(6):442–53.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab Invest. 1997;76(5):691–701.PubMedGoogle Scholar
  42. 42.
    Saito S, Hiroi Y, Zou Y, Aikawa R, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I. beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem. 2000;275(44):34528–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN, Sonnenblick EH. beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998;275(3 Pt 2):H961–8.PubMedGoogle Scholar
  44. 44.
    Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(6):1153–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Caforio AL, Bonifacio E, Stewart JT, Neglia D, Parodi O, Bottazzo GF, McKenna WJ. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol. 1990;15(7):1527–34.PubMedCrossRefGoogle Scholar
  46. 46.
    Caforio AL, Goldman JH, Haven AJ, Baig KM, Libera LD, McKenna WJ. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J. 1997;18(2):270–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee EY, Lee HL, Kim HT, Lee HD, Park JA. Clinical features and short-term outcomes of pediatric acute fulminant myocarditis in a single center. Korean J Pediatr. 2014;57(11):489–95.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    English RF, Janosky JE, Ettedgui JA, Webber SA. Outcomes for children with acute myocarditis. Cardiol Young. 2004;14(5):488–93.PubMedCrossRefGoogle Scholar
  49. 49.
    Freedman SB, Haladyn JK, Floh A, Kirsh JA, Taylor G, Thull-Freedman J. Pediatric myocarditis: emergency department clinical findings and diagnostic evaluation. Pediatrics. 2007;120(6):1278–85.PubMedCrossRefGoogle Scholar
  50. 50.
    Kim HJ, Yoo GH, Kil HR. Clinical outcome of acute myocarditis in children according to treatment modalities. Korean J Pediatr. 2010;53(7):745–52.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Canter CE, Simpson KP. Diagnosis and treatment of myocarditis in children in the current era. Circulation. 2014;129(1):115–28.PubMedCrossRefGoogle Scholar
  52. 52.
    Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991;18(7):1617–26.PubMedCrossRefGoogle Scholar
  53. 53.
    Cooper Jr LT. Acute heart failure due to fulminant and giant cell myocarditis. Herz. 2006;31(8):767–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Gupta S, Markham DW, Drazner MH, Mammen PP. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med. 2008;5(11):693–706.PubMedCrossRefGoogle Scholar
  55. 55.
    Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113(6):876–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36(1):227–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Sankar J, Khalil S, Jeeva Sankar M, Kumar D, Dubey N. Short-term outcomes of acute fulminant myocarditis in children. Pediatr Cardiol. 2011;32(7):885–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Teele SA, Allan CK, Laussen PC, Newburger JW, Gauvreau K, Thiagarajan RR. Management and outcomes in pediatric patients presenting with acute fulminant myocarditis. J Pediatr. 2011;158(4):638–43.e631.Google Scholar
  59. 59.
    Rajs J, Hammarquist F. Sudden infant death in Stockholm. A forensic pathology study covering ten years. Acta Paediatr Scand. 1988;77(6):812–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Dettmeyer R, Baasner A, Schlamann M, Padosch SA, Haag C, Kandolf R, Madea B. Role of virus-induced myocardial affections in sudden infant death syndrome: a prospective postmortem study. Pediatr Res. 2004;55(6):947–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D, Prutkin JM, Asif IM, Klossner D, Ackerman MJ. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes. Circ Arrhythm Electrophysiol. 2014;7(2):198–204.PubMedCrossRefGoogle Scholar
  62. 62.
    Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes 3rd NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527–35.PubMedCrossRefGoogle Scholar
  63. 63.
    Suarez-Mier MP, Aguilera B, Mosquera RM, Sanchez-de-Leon MS. Pathology of sudden death during recreational sports in Spain. Forensic Sci Int. 2013;226(1–3):188–96.PubMedCrossRefGoogle Scholar
  64. 64.
    Durani Y, Egan M, Baffa J, Selbst SM, Nager AL. Pediatric myocarditis: presenting clinical characteristics. Am J Emerg Med. 2009;27(8):942–7.PubMedCrossRefGoogle Scholar
  65. 65.
    May LJ, Patton DJ, Fruitman DS. The evolving approach to paediatric myocarditis: a review of the current literature. Cardiol Young. 2011;21(3):241–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol. 2015;115(4):499–504.PubMedCrossRefGoogle Scholar
  67. 67.
    Shekerdemian L, Bohn D. Acute viral myocarditis: epidemiology and pathophysiology. Pediatr Crit Care Med. 2006;7(6):S2–7.CrossRefGoogle Scholar
  68. 68.
    Daubeney PE, Nugent AW, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG; National Australian Childhood Cardiomyopathy Study. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation. 2006;114(24):2671–8.Google Scholar
  69. 69.
    Ichikawa R, Sumitomo N, Komori A, Abe Y, Nakamura T, Fukuhara J, Matsumura M, Miyashita M, Kanamaru H, Ayusawa M, Mugishima H. The follow-up evaluation of electrocardiogram and arrhythmias in children with fulminant myocarditis. Circ J. 2011;75(4):932–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Andrews RE, Fenton MJ, Ridout DA, Burch M, British Congenital Cardiac A. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation. 2008;117(1):79–84.PubMedCrossRefGoogle Scholar
  71. 71.
    Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867–76.PubMedCrossRefGoogle Scholar
  73. 73.
    Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52(4):274–88.PubMedCrossRefGoogle Scholar
  74. 74.
    Mendes LA, Dec GW, Picard MH, Palacios IF, Newell J, Davidoff R. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J. 1994;128(2):301–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Khoo NS, Smallhorn JF, Atallah J, Kaneko S, Mackie AS, Paterson I. Altered left ventricular tissue velocities, deformation and twist in children and young adults with acute myocarditis and normal ejection fraction. J Am Soc Echocardiogr. 2012;25(3):294–303.PubMedCrossRefGoogle Scholar
  76. 76.
    Escher F, Westermann D, Gaub R, Pronk J, Bock T, Al-Saadi N, Kuhl U, Schultheiss HP, Tschope C. Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. Heart. 2011;97(9):709–14.PubMedCrossRefGoogle Scholar
  77. 77.
    Kuhl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, Krautwurm L, Poller W, Schultheiss HP, Kandolf R. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108(8):945–50.PubMedCrossRefGoogle Scholar
  78. 78.
    Sagar S, Liu PP, Cooper Jr LT. Myocarditis. Lancet. 2012;379(9817):738–47.PubMedCrossRefGoogle Scholar
  79. 79.
    Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, Nguyen C, Cohen A, Slama MS, Steg PG, Le Guludec D. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol. 2001;37(3):786–92.PubMedCrossRefGoogle Scholar
  80. 80.
    Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.Google Scholar
  81. 81.
    Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is “alive” is not enough. Heart. 2004;90(2):137–40.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Pattynama PM, De Roos A, Van der Wall EE, Van Voorthuisen AE. Evaluation of cardiac function with magnetic resonance imaging. Am Heart J. 1994;128(3):595–607.PubMedCrossRefGoogle Scholar
  83. 83.
    Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475–87.Google Scholar
  84. 84.
    Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.PubMedCrossRefGoogle Scholar
  85. 85.
    Aletras AH, Kellman P, Derbyshire JA, Arai AE. ACUT2E TSE-SSFP: a hybrid method for T2-weighted imaging of edema in the heart. Magn Reson Med. 2008;59(2):229–35.PubMedCrossRefGoogle Scholar
  86. 86.
    Liu PP, Yan AT. Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: prospects for detecting myocardial inflammation. J Am Coll Cardiol. 2005;45(11):1823–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215–23.PubMedCrossRefGoogle Scholar
  88. 88.
    Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Fritz P, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio Jr JJ, Olsen EG, Schoen FJ. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1(1):3–14.PubMedGoogle Scholar
  90. 90.
    Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64(10):1235–45.PubMedCrossRefGoogle Scholar
  91. 91.
    Wu LA, Lapeyre 3rd AC, Cooper LT. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin Proc. 2001;76(10):1030–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.Google Scholar
  94. 94.
    Herskowitz A, Ahmed-Ansari A, Neumann DA, Beschorner WE, Rose NR, Soule LM, Burek CL, Sell KW, Baughman KL. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol. 1990;15(3):624–32.PubMedCrossRefGoogle Scholar
  95. 95.
    Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104(1):39–45.PubMedCrossRefGoogle Scholar
  96. 96.
    Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857–63.PubMedCrossRefGoogle Scholar
  97. 97.
    Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol. 2010;31(2):222–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev. 2013;18(6):761–95.PubMedCrossRefGoogle Scholar
  99. 99.
    Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Friedman RA, Kearney DL, Moak JP, Fenrich AL, Perry JC. Persistence of ventricular arrhythmia after resolution of occult myocarditis in children and young adults. J Am Coll Cardiol. 1994;24(3):780–3.PubMedCrossRefGoogle Scholar
  101. 101.
    Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J. 2015;79(1):4–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333(5):269–75.PubMedCrossRefGoogle Scholar
  103. 103.
    Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252–7.PubMedCrossRefGoogle Scholar
  104. 104.
    McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103(18):2254–9.PubMedCrossRefGoogle Scholar
  105. 105.
    Meune C, Spaulding C, Mahe I, Lebon P, Bergmann JF. Risks versus benefits of NSAIDs including aspirin in myocarditis: a review of the evidence from animal studies. Drug Saf. 2003;26(13):975–81.PubMedCrossRefGoogle Scholar
  106. 106.
    Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK, Kanter KR, Higgins RS, Blume ED, Rosenthal DN, Boucek MM, Uzark KC, Friedman AH, Young JK; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;115(5):658–76.Google Scholar
  107. 107.
    Shirali GS, Ni J, Chinnock RE, Johnston JK, Rosenthal GL, Bowles NE, Towbin JA. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med. 2001;344(20):1498–503.PubMedCrossRefGoogle Scholar
  108. 108.
    Pietra BA, Kantor PF, Bartlett HL, Chin C, Canter CE, Larsen RL, Edens RE, Colan SD, Towbin JA, Lipshultz SE, Kirklin JK, Naftel DC, Hsu DT. Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy. Circulation. 2012;126(9):1079–86.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Garbern JC, Gauvreau K, Blume ED, Singh TP. Is myocarditis an independent risk factor for post-transplant mortality in pediatric heart transplant recipients? Circ Heart Fail. 2016;9(1):e002328.PubMedCrossRefGoogle Scholar
  110. 110.
    Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, Cooper LT, Link MS, Maron MS. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. Circulation. 2015;132(22):e273–80.PubMedCrossRefGoogle Scholar
  111. 111.
    Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med. 2004;351(21):2195–202.PubMedCrossRefGoogle Scholar
  112. 112.
    Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH; Task Force on the Diagnosis and Management of Pricardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J. 2004;25(7):587–610.Google Scholar
  113. 113.
    Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet. 2004;363(9410):717–27.PubMedCrossRefGoogle Scholar
  114. 114.
    Geggel RL. Conditions leading to pediatric cardiology consultation in a tertiary academic hospital. Pediatrics. 2004;114(4):e409–17.PubMedCrossRefGoogle Scholar
  115. 115.
    Ratnapalan S, Brown K, Benson L. Children presenting with acute pericarditis to the emergency department. Pediatr Emerg Care. 2011;27(7):581–5.PubMedCrossRefGoogle Scholar
  116. 116.
    Permanyer-Miralda G, Sagrista-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol. 1985;56(10):623–30.PubMedCrossRefGoogle Scholar
  117. 117.
    Levy PY, Corey R, Berger P, Habib G, Bonnet JL, Levy S, Messana T, Djiane P, Frances Y, Botta C, DeMicco P, Dumon H, Mundler O, Chomel JJ, Raoult D. Etiologic diagnosis of 204 pericardial effusions. Medicine (Baltimore). 2003;82(6):385–91.CrossRefGoogle Scholar
  118. 118.
    Dery P, Marks MI, Shapera R. Clinical manifestations of coxsackievirus infections in children. Am J Dis Child. 1974;128(4):464–8.PubMedGoogle Scholar
  119. 119.
    Shimizu C, Rambaud C, Cheron G, Rouzioux C, Lozinski GM, Rao A, Stanway G, Krous HF, Burns JC. Molecular identification of viruses in sudden infant death associated with myocarditis and pericarditis. Pediatr Infect Dis J. 1995;14(7):584–8.PubMedCrossRefGoogle Scholar
  120. 120.
    Satoh T, Kojima M, Ohshima K. Demonstration of the Epstein-Barr genome by the polymerase chain reaction and in situ hybridisation in a patient with viral pericarditis. Br Heart J. 1993;69(6):563–4.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Dressler W. Effect of respiration on the pericardial friction rub. Am J Cardiol. 1961;7:130–1.PubMedCrossRefGoogle Scholar
  122. 122.
    Farringer Jr JL, Carr D. Cardiac tamponade. Ann Surg. 1955;141(4):437–42.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–16.PubMedCrossRefGoogle Scholar
  124. 124.
    Strauss AW, Santa-Maria M, Goldring D. Constrictive pericarditis in children. Am J Dis Child. 1975;129(7):822–6.PubMedGoogle Scholar
  125. 125.
    Sagrista Sauleda J, Permanyer Miralda G, Soler Soler J. [Diagnosis and management of acute pericardial syndromes]. Rev Esp Cardiol. 2005;58(7):830–41Google Scholar
  126. 126.
    Spodick DH. The normal and diseased pericardium: current concepts of pericardial physiology, diagnosis and treatment. J Am Coll Cardiol. 1983;1(1):240–51.PubMedCrossRefGoogle Scholar
  127. 127.
    Garcia MJ. Constrictive pericarditis versus restrictive cardiomyopathy? J Am Coll Cardiol. 2016;67(17):2061–76.PubMedCrossRefGoogle Scholar
  128. 128.
    Bonnefoy E, Godon P, Kirkorian G, Fatemi M, Chevalier P, Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J. 2000;21(10):832–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Feng D, Glockner J, Kim K, Martinez M, Syed IS, Araoz P, Breen J, Espinosa RE, Sundt T, Schaff HV, Oh JK. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation. 2011;124(17):1830–7.PubMedCrossRefGoogle Scholar
  130. 130.
    Khandaker MH, Espinosa RE, Nishimura RA, Sinak LJ, Hayes SN, Melduni RM, Oh JK. Pericardial disease: diagnosis and management. Mayo Clin Proc. 2010;85(6):572–93.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Teh BS, Walsh J, Bell AJ, Walker SJ, Kilpatrick D. Electrical current paths in acute pericarditis. J Electrocardiol. 1993;26(4):291–300.PubMedCrossRefGoogle Scholar
  132. 132.
    Lau TK, Civitello AB, Hemandez A, Coulter SA. Cardiac tamponade and electrical alternans. Tex Heart Inst J. 2002;29(1):66–7.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Kahlert P, Katz MA, Buck T, Erbel R. Electrical alternans due to cardiac tamponade. Herz. 2005;30(2):151–2.PubMedCrossRefGoogle Scholar
  134. 134.
    Imazio M, Adler Y. Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev. 2013;18(3):355–60.PubMedCrossRefGoogle Scholar
  135. 135.
    Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, Pomari F, Coda L, Belli R, Trinchero R. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739–44.PubMedCrossRefGoogle Scholar
  136. 136.
    Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186–97.PubMedCrossRefGoogle Scholar
  137. 137.
    LeWinter MM. Acute pericarditis. N Engl J Med. 2014;371(25):2410–6.PubMedCrossRefGoogle Scholar
  138. 138.
    Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio AL, Carerj S, Ceconi C, Evangelista A, Flachskampf F, Giannakoulas G, Gielen S, Habib G, Kolh P, Lambrinou E, Lancellotti P, Lazaros G, Linhart A, Meurin P, Nieman K, Piepoli MF, Price S, Roos-Hesselink J, Roubille F, Ruschitzka F, Sagrista Sauleda J, Sousa-Uva M, Uwe Voigt J, Luis Zamorano J; European Society of Cardiology (ESC). 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64.Google Scholar
  139. 139.
    Burch GE, Tsui CY. Evolution of coxsackie viral valvular and mural endocarditis in mice. Br J Exp Pathol. 1971;52(4):360–4.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Burch GE, DePasquale NP, Sun SC, Mogabgab WJ, Hale AR. Endocarditis in mice infected with coxsackie virus B4. Science. 1966;151(3709):447–8.PubMedCrossRefGoogle Scholar
  141. 141.
    Blumental S, Reynders M, Willems A, Biarent D, Duttman R, Lepage P, Vergison A. Enteroviral infection of a cardiac prosthetic device. Clin Infect Dis. 2011;52(6):710–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Fournier PE, Charrel R, Raoult D. Viral endocarditis or simple viral disseminated infection? Clin Infect Dis. 2011;53(12):1298; author reply 1299–1300.Google Scholar
  143. 143.
    Starc TJ, Lipshultz SE, Kaplan S, Easley KA, Bricker JT, Colan SD, Lai WW, Gersony WM, Sopko G, Moodie DS, Schluchter MD. Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Pediatrics. 1999;104(2):e14.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Lipshultz SE, Chanock S, Sanders SP, Colan SD, Perez-Atayde A, McIntosh K. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol. 1989;63(20):1489–97.PubMedCrossRefGoogle Scholar
  145. 145.
    Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296(7):844–54.PubMedCrossRefGoogle Scholar
  146. 146.
    Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151(6):1147–55.PubMedCrossRefGoogle Scholar
  147. 147.
    Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Colan SD. Cardiac dysfunction and mortality in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation. 2000;102(13):1542–8.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, Beschorner WE, Baughman KL. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol. 1994;24(4):1025–32.PubMedCrossRefGoogle Scholar
  149. 149.
    Barbaro G. Cardiovascular manifestations of HIV infection. J R Soc Med. 2001;94(8):384–90.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Children’s Mercy Hospital and Clinics, University of Missouri-Kansas CityKansas CityUSA
  2. 2.St. Louis Children’s Hospital, Washington University in St. LouisSt. LouisUSA

Personalised recommendations